ESTUDIO RETROSPECTIVO PARA DESCRIBIR LA INCIDENCIA DE REACCIONES ALERGICAS MODERADAS A GRAVES DEL FACTOR IX EN PACIENTES CON HEMOFILIA B.

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021

• 
• 5

  

Challenges, questions and opportunities with regard to the new relationship between clinical practice and the haemostasis laboratory: the path towards personalized medicine.

Cid AR

Article. 10.1097/MBC.0000000000001091. 2021

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.

Fischer K; (...); Königs C

Article. 10.1182/bloodadvances.2023011442. 2024

• 
• 
• 1

  

Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024

DIAGNOSIS AND MANAGEMENT OF HEMARTHROSIS AND HAEMOPHILIC ARTHROPATHY USING UNIFIED CLINICAL AND ULTRASOUND CRITERIA: PRELIMINARY RESULTS

Chimeno-Hernandez, A; (...); Querol, F

Meeting Abstract. 2021

Efficacy and safety evaluation of Fanhdi ® , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.

Jimenez-Yuste, Victor; (...); Paez, Antonio

Letter. 10.1111/hae.14453. 2022

• 
• 
• 4

  

Emicizumab-induced photosensitivity.

Asensi Canto, Pedro; (...); Haya Guaita, Saturnino

Article. 10.1055/s-0042-1749092. 2022

• 
• 1

  

FEIBA GLOBAL OUTCOME (FEIBA GO) STUDY: REAL-WORLD DATA IN PATIENTS WITH CONGENITAL HEMOPHILIA AND INHIBITORS

Hermans, C; (...); Windyga, J

Meeting Abstract. 2021

Haemotrack: Musculoskeletal management in haemophilia with physiotherapist-driven digital solutions

Perez-Alenda, Sofia; (...); Aguilar-Rodriguez, Marta

Meeting Abstract. 2024

IMPACT OF INITIATION OF PROPHYLAXIS, SYNOVITIS AND FUNCTIONALITY ON JOINT HEALTH IN PATIENTS WITH HEMOPHILIA

Chimeno, A.; (...); Bonanad Boix, S.

Meeting Abstract. 2023

Less common hemorrhagic coagulopathies in women.

Cid AR

Article. 10.1097/MBC.0000000000000990. 2020

Management of acquired hemophilia A: results from the Spanish registry.

Mingot-Castellano ME; (...); Marco P

Article. 10.1182/bloodadvances.2021004626. 2021

• 
• 
• 29

  

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.

Megias-Vericat, J. E.; (...); Poveda Andres, J. L.

Article. 10.1016/j.thromres.2022.06.001. 2022

• 
• 7

  

Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.

Megias-Vericata, J. E.; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2023.11.023. 2023

• 
• 1

  

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.

Ettingshausen CE; (...); Windyga J

Article. 10.1177/20406207231184323. 2023

• 
• 
• 3

  

The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology

Gresele, P; (...); BAT-VAL Study Investigators

Article. 10.1111/jth.15263. 2021

• 
• 
• 27

  

Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project

Perez-Rodriguez, Almudena; (...); Lopez-Fernandez, Maria Fernanda

Article. 10.1111/hae.14405. 2021

• 
• 4